非酒精性脂肪性肝病与代谢相关脂肪性肝病在 TARGET-NASH 真实世界队列中具有高度一致性。
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
机构信息
UNC Liver Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Target RWE, Durham, North Carolina, USA.
出版信息
Am J Gastroenterol. 2024 Aug 1;119(8):1624-1627. doi: 10.14309/ajg.0000000000002796. Epub 2024 Apr 8.
INTRODUCTION
This study investigates the applicability of the new metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature to the real-world TARGET-NASH US adult cohort.
METHODS
The new MASLD/metabolic steatohepatitis nomenclature was applied to patients enrolled with pragmatic diagnoses of nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), and NASH cirrhosis and concordance were determined between the definitions.
RESULTS
Approximately 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. Approximately 1,484/1,541 (96.3%, kappa 0.974) nonalcoholic fatty liver patients (metabolic dysfunction-associated steatotic liver), 2,195/2,201 (99.7%, kappa 0.998) NASH patients (metabolic steatohepatitis), and 1,999/2,003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria.
DISCUSSION
The new MASLD nomenclature is highly concordant with the previous TARGET-NASH pragmatic definitions.
简介
本研究旨在探讨新的代谢相关脂肪性肝病（MASLD）命名法在真实世界 TARGET-NASH 美国成年队列中的适用性。
方法
将新的 MASLD/代谢性脂肪性肝炎命名法应用于符合非酒精性脂肪性肝病和非酒精性脂肪性肝炎（NASH）的患者，并确定这些定义之间的一致性。
结果
大约 99%的 TARGET-NASH 参与者符合新的 MASLD 诊断标准。大约 1484/1541（96.3%，kappa 值为 0.974）例非酒精性脂肪性肝病患者（代谢相关脂肪性肝病）、2195/2201（99.7%，kappa 值为 0.998）例 NASH 患者（代谢性脂肪性肝炎）和 1999/2003（99.8%，kappa 值为 0.999）例 NASH 肝硬化患者符合新的标准。
讨论
新的 MASLD 命名法与之前的 TARGET-NASH 实用定义高度一致。
Zotero 插件